by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Hanlim Pharm Co., Ltd. Warning Letter Details

Warning Letter

Hanlim Pharm Co., Ltd.

Hanlim Pharm Co., Ltd., Seocho-Daero, 52-Gil 42 Seongdong-gu Seoul South Korea, (b)(4)

Issue DateOctober 02, 2026

FEI Number3004886113

Violations4

CountrySouth Korea

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

CGMP/Finished Pharmaceuticals/Adulterated

Hanlim Pharm Co., Ltd. FDA Warning Letter, October 2, 2026